Author

Xu Zhang

Institution: Gilead Sciences (United States)

Observed institution: Gilead Sciences (United States)

OpenAlex ID: A5126851163

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

2026 · Chloe Orkin, Chloe Orkin, et al. · The Lancet · 5

Changing to a once-a-day single pill of bictegravir/lenacapavir from complex HIV treatment: a plain language summary of the ARTISTRY-1 study up to 1 year

2026 · Chloe Orkin, Peter J. Ruane, et al. · Future Virology

Works count: 2

Citation count: 5

H-index: 1

I10-index: